A detailed history of Manufacturers Life Insurance Company, The transactions in Annexon, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 159,586 shares of ANNX stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
159,586
Previous 157,136 1.56%
Holding current value
$1.05 Million
Previous $769,000 22.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.49 - $7.2 $11,000 - $17,640
2,450 Added 1.56%
159,586 $944,000
Q2 2024

Aug 14, 2024

BUY
$4.33 - $6.79 $274,218 - $430,010
63,330 Added 67.51%
157,136 $769,000
Q1 2024

May 14, 2024

BUY
$4.03 - $7.81 $297,353 - $576,260
73,785 Added 368.54%
93,806 $672,000
Q2 2023

Aug 11, 2023

SELL
$2.1 - $6.37 $49,219 - $149,300
-23,438 Reduced 53.93%
20,021 $70,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $91,698 - $176,443
-43,459 Closed
0 $0
Q1 2022

Aug 11, 2023

BUY
$2.73 - $11.94 $118,643 - $518,900
43,459 New
43,459 $118,000
Q1 2022

May 20, 2022

BUY
$2.73 - $11.94 $71,367 - $312,135
26,142 Added 150.96%
43,459 $121,000
Q4 2021

Feb 16, 2022

BUY
$11.49 - $22.0 $4,113 - $7,876
358 Added 2.11%
17,317 $201,000
Q3 2021

Nov 12, 2021

SELL
$16.35 - $23.4 $17,870 - $25,576
-1,093 Reduced 6.05%
16,959 $316,000
Q2 2021

Aug 12, 2021

BUY
$17.81 - $27.48 $55,300 - $85,325
3,105 Added 20.77%
18,052 $406,000
Q1 2021

May 03, 2021

BUY
$22.0 - $35.01 $119,724 - $190,524
5,442 Added 57.25%
14,947 $416,000
Q4 2020

Feb 12, 2021

BUY
$20.81 - $30.55 $33,483 - $49,154
1,609 Added 20.38%
9,505 $238,000
Q3 2020

Nov 09, 2020

BUY
$17.5 - $30.23 $138,180 - $238,696
7,896 New
7,896 $239,000

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $312M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.